Kilitch Drugs (India)NSE:KILITCH -0.62%84 Days Inventory is 23.81 as of Mar. 2026, which is 41% below its 10-year median of 40.60. GuruFocus rates NSE:KILITCH with a GF Score™ of 84/100 and a GF Value™ of ₹226.33 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 919 Drug Manufacturers companies, Kilitch Drugs (India) ranks better than 95.43% on this metric.
The historical rank and industry rank for Kilitch Drugs (India)'s Days Inventory or its related term are showing as below:
NSE:KILITCH'
s Days Inventory Range Over the Past 10 Years
Min: 18.12 Med: 40.6 Max: 81.58
Current: 44.22
During the past 13 years, Kilitch Drugs (India)'s highest Days Inventory was 81.58. The lowest was 18.12. And the median was 40.60.
NSE:KILITCH's Days Inventory is ranked better than 95.43% of 919
companies
in the Drug Manufacturers industry
Industry Median: 164.38
vs NSE:KILITCH: 44.22
Kilitch Drugs (India)'s Days Inventory
declined
from Mar. 2025 (68.61) to Mar. 2026 (23.81).
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Kilitch Drugs (India)'s Inventory Turnover for the
three
months ended in Mar. 2026 was 3.83.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Kilitch Drugs (India)'s Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.13.
Kilitch Drugs (India) (NSE:KILITCH) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Kilitch Drugs (India)'s Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Kilitch Drugs (India)'s Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Kilitch Drugs (India) Days Inventory Related Terms
Kilitch Drugs (India) Days Inventory Historical Data
* Premium members only.
The historical data trend for Kilitch Drugs (India)'s Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:KILITCH vs ZTS, UTHR: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kilitch Drugs (India)'s Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kilitch Drugs (India) Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kilitch Drugs (India)'s Days Inventory distribution charts can be found below:
* The bar in red indicates where Kilitch Drugs (India)'s Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kilitch Drugs (India) (NSE:KILITCH) has a Days Inventory of 23.81 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Kilitch Drugs (India) and its competitors. This is 41% below median its historical median of 40.60. Over the past decade, Kilitch Drugs (India)'s Days Inventory has ranged from 18.12 to 81.58. According to the industry distribution chart, Kilitch Drugs (India) ranks #42 out of 919 companies in the Drug Manufacturers industry, placing it in the top 4.6%.
Is Kilitch Drugs (India)'s Days Inventory too high?
Kilitch Drugs (India)'s current Days Inventory of 23.81 is 41% below median its 10-year median of 40.60. Over the past 10 years, this metric has ranged from a low of 18.12 to a high of 81.58. The Drug Manufacturers industry median Days Inventory is 164.38. Kilitch Drugs (India)'s value of 23.81 is 85.5% below this industry median. Based on the distribution chart, Kilitch Drugs (India) ranks #42 out of 919 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kilitch Drugs (India) has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kilitch Drugs (India)'s Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kilitch Drugs (India) ranks #42 out of 919 companies for Days Inventory. This places Kilitch Drugs (India) in the top 5% of its industry — outperforming the majority of peers. The industry median Days Inventory is 164.38. Kilitch Drugs (India)'s value of 23.81 is 85.5% below this benchmark. Historically, Kilitch Drugs (India)'s own Days Inventory has ranged from 18.12 to 81.58 over the past decade. While the company's 10-year median is 40.60 vs. the industry median of 164.38, Kilitch Drugs (India) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.38, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kilitch Drugs (India)'s current Days Inventory of 23.81 is 85.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Kilitch Drugs (India) and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kilitch Drugs (India)'s current Days Inventory is 23.81, which is 41% below median its own 10-year median of 40.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kilitch Drugs (India) stock overvalued right now?
Based on GuruFocus' analysis, Kilitch Drugs (India) (NSE:KILITCH) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹226.33, compared to a current price of ₹183.10 — trading 19.1% below its estimated fair value. The current Days Inventory is 23.81, which is 41% below median its 10-year median of 40.60 and 85.5% below the Drug Manufacturers industry median of 164.38. Kilitch Drugs (India)'s overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Kilitch Drugs (India) (NSE:KILITCH), the current Days Inventory is 23.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kilitch Drugs (India) (NSE:KILITCH) Overvalued in 2026?
Based on GuruFocus' analysis, Kilitch Drugs (India) stock appears to be undervalued.
The current stock price of ₹183.10 is trading 19.1% below its estimated GF Value™ of ₹226.33.
GuruFocus considers Kilitch Drugs (India) to be Modestly Undervalued.
Key valuation signals for NSE:KILITCH:
Days Inventory: 23.81 (41% below median its 10-year median of 40.60)
GF Value™: ₹226.33 vs. price of ₹183.10 (19.1% below fair value)
Industry Position: 85.5% below the Drug Manufacturers median (#42 of 919)
No single metric tells the full story. See the NSE:KILITCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in operation and management of Pharmaceutical Products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, and HPURE. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.
84GF Score
Get the complete analysis for NSE:KILITCH
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:KILITCH has been successfully added to your 
